Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > McWhirter

<< Previous

Bullboard Posts

Next >>

Comment by Duster340on May 11, 2021 1:00am

129 Views

Post# 33171518

RE:McWhirter

BobbyJr5 wrote: Hopefully on Thursday he'll provide some commentary on the status of ATE now that the intellectual property has been sorted out

my guess is mcwhirter does not take any calls on ate, i think he is tired of pumping this one for now, when september rolls around he will be back on the bandwagon.

<< Previous

Bullboard Posts

Next >>

Southern Ontario mineral processing operation receives green fund support